Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (605)	2/19/1999 12:34:00 PM
From: LLCF	Read Replies (1) \| Respond to of 1073

Looks like a CEPH type investor showing up in SCIO... sold 500 July 10's and bought stock... a trend here? Maybe some (one? ha ha ha) institutional types coming down to stocks with approved products? DAK

To: scaram(o)uche who wrote (605)	2/20/1999 1:34:00 PM
From: JOEBT1	Read Replies (1) \| Respond to of 1073

Richard--Relative to your question of getting a " bulky antibody to sites of interest within a solid tumor", it was successfully accomplished in mice for colon, pancreatic and non-small cell lung cancer. As Mitch described it to me, they induced human pancreatic cancer in mice and allowed it to balloon up with cancer. They injected C242-DM1 in the tail vein once and in 10 days the cancer was eradicated. They waited 200 days and did an autopsy and found no cancer. C242 does have a specific antigenic site for these cancer cells. There was no antibody produced against the hapten in mice or primates. The half-life in primates for C242-DM1 was sufficient for C242-DM1 to work.(no cancer was induced in primates--just a safety test--no ill effects in primates). Relative to humanization IMGN asked another company to humanize C242 and the molecule produced was identical to the molecule produced by IMGN's humanization process. Richard, I know your skeptical of mice results but I'll continue to try to get better answers to your questions. SKB in doing their DD repeated the animal tests and replicated the results. I agree the deal isn't super but for a drug that hasn't been in human trials you got to admit it's pretty good.